Latest Cynapsus Therapeutic (CYNAF) Headlines
Post# of 9
Posted On: 03/09/2014 1:34:11 PM
Latest Cynapsus Therapeutic (CYNAF) Headlines
Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement of transfers of its common shares in the United States.
Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.
LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)
Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.
Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.
Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.
SeeThruEquity, LLC Initiates Coverage on Cynapsus Therapeutics Inc.
Marketwire - Tue Nov 26, 8:03AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.
Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Nov 21, 3:43PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the nine months ended September 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Aug 22, 3:18PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the six months ended June 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report
Marketwire - Mon Aug 05, 8:37AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States
Marketwire - Thu Jul 18, 6:07AM CDT
July 18, 2013
Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement of transfers of its common shares in the United States.
Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.
LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)
Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.
Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.
Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.
SeeThruEquity, LLC Initiates Coverage on Cynapsus Therapeutics Inc.
Marketwire - Tue Nov 26, 8:03AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.
Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Nov 21, 3:43PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the nine months ended September 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent Developments
Marketwire - Thu Aug 22, 3:18PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the six months ended June 30, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report
Marketwire - Mon Aug 05, 8:37AM CDT
Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States
Marketwire - Thu Jul 18, 6:07AM CDT
July 18, 2013
(0)
(0)Cynapsus Therapeutics Inc. (CYNA) Stock Research Links
Scroll down for more posts ▼